Viking Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2026
VKTX$28.66-1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
(In thousands, except per share amounts)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Revenues | $— | $— | $— |
| Operating expenses: | |||
| Research and development | 344,955 | 101,644 | 63,806 |
| General and administrative | 48,387 | 49,277 | 37,021 |
| Total operating expenses | 393,342 | 150,921 | 100,827 |
| Loss from operations | (393,342) | (150,921) | (100,827) |
| Other income (expense): | |||
| Amortization of financing costs | (56) | (94) | (88) |
| Interest income, net | 33,704 | 40,940 | 15,020 |
| Realized gain on investments, net | 55 | 112 | — |
| Total other income, net | 33,703 | 40,958 | 14,932 |
| Net loss | (359,639) | (109,963) | (85,895) |
| Other comprehensive loss, net of tax: | |||
| Unrealized gain (loss) on securities | 1,119 | (173) | 742 |
| Foreign currency translation gain (loss) | 47 | (226) | (29) |
| Comprehensive loss | $(358,473) | $(110,362) | $(85,182) |
| Basic and diluted net loss per share | $(3.19) | $(1.01) | $(0.91) |
| Weighted-average shares used to compute basic and diluted net loss per share | 112,667 | 109,037 | 94,347 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.